Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
ConclusionThese findings strongly suggest that TMC-DS-L NPs loaded with siRNA could act as a novel tool in inhibiting the expression of immune checkpoints in the tumor microenvironment. Also, combination therapy based on inhibition of PD-1 and LAG3 in combination with DC vaccine is an effective method in treating cancer that needs to be further studied.
Source: Pharmaceutical Research - June 17, 2022 Category: Drugs & Pharmacology Source Type: research

Viruses, Vol. 14, Pages 657: HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
ung Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer. Functional HBV cure defined as hepatitis B surface antigen (HBsAg) loss and undetectable serum HBV DNA is associated with improved clinical outcomes in patients with chronic HBV infection. However, spontaneous loss of HBsAg is rare and occurs in only 1% of all HBsAg-positive individuals annually. Furthermore, the rate of functional cure with currently available antiviral therapy is eve...
Source: Viruses - March 22, 2022 Category: Virology Authors: Maryam Moini Scott Fung Tags: Review Source Type: research

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
CONCLUSION: Our findings suggest a potential combination approach for cancer immunotherapy using PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs and PLGA (antigen+adjuvant)-NPs as novel immune checkpoint silencing agents.PMID:35228265 | DOI:10.1136/jitc-2021-003928
Source: Cancer Control - March 1, 2022 Category: Cancer & Oncology Authors: Ji Eun Won Youngseon Byeon Tae In Wi Chan Mi Lee Ju Hyeong Lee Tae Heung Kang Jeong-Won Lee YoungJoo Lee Yeong-Min Park Hee Dong Han Source Type: research

Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
CONCLUSIONS: These findings suggest that the use of new nanocarriers such as SPION-C-CMD-FA could be an effective way to use as a novel combination therapy consisting of β-catenin siRNA, IL-15, and DC vaccine to treat cancer.PMID:35166995 | DOI:10.1007/s11095-022-03169-2
Source: Cell Research - February 15, 2022 Category: Cytology Authors: Armin Mahmoud Salehi Kheshti Farnaz Hajizadeh Asal Barshidi Bentolhoda Rashidi Farbod Ebrahimi Simin Bahmanpour Vahid Karpisheh Fatemeh Karimian Noukabadi Fariba Karoon Kiani Hadi Hassannia Fatemeh Atyabi Seyed Hossein Kiaie Fatah Kashanchi Jamshid Gholiz Source Type: research

Delivery Strategies for mRNA Vaccines
AbstractThe therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) approval of patisiran (Onpattro ™) for hereditary ATTR amyloidosis. This was largely made possible by major advances in the formulation technology for stabilized lipid-based nanoparticles (LNPs). Design of the cationic ionizable lipids, which are a key component of the LNP formulations, with an acid dissociation constan...
Source: Pharmaceutical Medicine - January 30, 2022 Category: Drugs & Pharmacology Source Type: research

Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer
Biomaterials. 2021 Dec 2;280:121306. doi: 10.1016/j.biomaterials.2021.121306. Online ahead of print.ABSTRACTDespite tremendous progress achieved in immunotherapy, many critical challenges in treating pancreatic ductal adenocarcinoma (PDAC) persist. Considering the poor vascularization of PDAC, after intramuscular administration exosomes can targeted deliver "cargos" to pancreatic tumors and bypass obstructions of the intrinsic overexpressed stroma through lymphatics. Herein, we propose a strategy to derive exosomes from immunogenically dying tumor cells and exploit their properties for several purposes, including antigen p...
Source: Biomaterials - December 24, 2021 Category: Materials Science Authors: Wenxi Zhou Xinli Chen Yu Zhou Si Shi Chen Liang Xianjun Yu Hongyi Chen Qin Guo Yiwen Zhang Peixin Liu Chao Li Yongchao Chu Yifan Luo Yu Wang Zheng Zhou Zhenhao Zhao Qinjun Chen Tao Sun Chen Jiang Source Type: research

PCSK9 as a new player in cancer: New opportunity or red herring?
Curr Med Chem. 2021 Nov 15. doi: 10.2174/0929867328666211115122324. Online ahead of print.ABSTRACTInitially described as a factor involved in liver regeneration and neuronal differentiation, proprotein convertase subtilisin/kexin type 9 (PCSK9) has become one of the key regulators of low-density lipoprotein cholesterol. Besides that, a number of studies have suggested PCSK9 may play a role in cancer biology. This is particularly true for gastroenteric (gastric and liver cancers) and lung cancers, where higher PCSK9 levels were associated with the increased ability of the tumor to develop and give metastasis as well as with...
Source: Current Medicinal Chemistry - November 16, 2021 Category: Chemistry Authors: Aldo Bonaventura Alessandra Vecchi é Massimiliano Ruscica Francesco Grossi Francesco Dentali Source Type: research

Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing
Acc Chem Res. 2021 Oct 20. doi: 10.1021/acs.accounts.1c00500. Online ahead of print.ABSTRACTConspectusSince the U.S. Food and Drug Administration (FDA) granted emergency use authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has attracted broad attention from the scientific community to investors. When delivered intracellularly, mRNA has the ability to produce various therapeutic proteins, enabling the treatment of a variety of illnesses, including but not limited to infectious diseases, cancers, and genetic diseases. Accordingly, mRNA holds significant therapeutic potential and provides a promis...
Source: Cell Research - October 20, 2021 Category: Cytology Authors: Min Qiu Yamin Li Hanan Bloomer Qiaobing Xu Source Type: research

Therapeutic DNA vaccine encoding CEMIP (KIAA1199) ameliorates kidney fibrosis in obesity through inhibiting the Wnt/ β-catenin pathway
CONCLUSION: DNA vaccine targeting CEMIP/Wnt1/β-catenin pathway plays a novel strategy in nephropathy.GENERAL SIGNIFICANCE: Immune therapy might provide a new therapeutic option on nephropathy of obesity.PMID:34582938 | DOI:10.1016/j.bbagen.2021.130019
Source: Biochimica et Biophysica Acta - September 28, 2021 Category: Biochemistry Authors: Chao-Hung Chen Guan-Ming Ke Pi-Chen Lin Kun-Der Lin Source Type: research

Synergistic Effect of NF- κB Signaling Pathway Inhibitor and Oncolytic 
Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms
Conclusion The combination of NF-κB signaling pathway inhibitor pS1145 and oncolytic measles virus vaccine strains can promote the apoptosis of human lung cancer cells A549 and H1299 and enhance their oncolytic effect.
 DOI: 10.3779/j.issn.1009-3419.2021.102.14
Source: Chinese Journal of Lung Cancer - April 20, 2021 Category: Cancer & Oncology Source Type: research